The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Receiving CAR T therapy sooner may improve lymphoma survival

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

According to the results of the ZUMA-7 clinical trial, the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
By Matthew Bin Han Ong
Drugs & Targets

EMA CHMP adopts positive opinion for Tepkinly in R/R follicular lymphoma

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the granting of conditional marketing authorization of Tepkinly (epcoritamab), a T-cell engaging bispecific antibody administered subcutaneously, as a monotherapy for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. 
Clinical Roundup

Columvi combination extends OS in transplant-ineligible R/R DLBCL in phase III trial

In the phase III STARGLO study of Columvi (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan (rituximab) in combination with GemOx (R-GemOx) for people with relapsed or refractory diffuse large B-cell lymphoma who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, or who have received two or more prior lines of therapy, the Columvi regiment extended overall survival.
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account